SK Chemicals CEO Ahn Jae-hyun, left, greets Turkish President Recep Tayyip Erdogan during a groundbreaking ceremony for SK Plasma’s blood product-based therapeutics plant in Turkey, Thursday (local time). Courtesy of SK Chemicals
SK Plasma has broken ground on a plasma-derived therapeutics manufacturing plant in Turkey, moving a long-planned project to localize production of critical medicines into the execution phase.
The company said Monday that it held a groundbreaking ceremony at the plant site in Çubuk, Ankara, through Proturk, a joint venture established with the Turkish Red Crescent.
Under the project, Proturk will build a facility with annual plasma-processing capacity of 600,000 liters and a total floor area of about 36,000 square meters.
The plant is scheduled for completion in the second half of 2028, with commercial production targeted for 2030.
